Matrixyl (Palmitoyl Pentapeptide-4) Peptide

Matrixyl (Palmitoyl Pentapeptide-4, Pal-KTTKS) is one of the most extensively studied cosmetic peptides. Research by Sederma showed it stimulates collagen I synthesis by 117%, collagen IV by 327%, and hyaluronic acid by 267% in fibroblast cultures. The palmitoyl chain enhances skin penetration.

Matrixyl, known chemically as palmitoyl pentapeptide-4 (Pal-KTTKS), exerts its dermal effects through a biomimetic signaling mechanism that imitates a procollagen I C-terminal propeptide fragment. The pentapeptide sequence Lys-Thr-Thr-Lys-Ser (KTTKS) is derived from the type I procollagen propeptide region that is normally cleaved during collagen biosynthesis and remains bioactive in the dermal microenvironment. The palmitoyl (C16 fatty acid) moiety covalently linked to the N-terminal lysine substantially increases the lipophilicity of the peptide, enabling penetration through the stratum corneum lipid barrier — a property critical for any topical anti-aging research compound.

1. Procollagen Feedback Signaling. KTTKS functions as a positive feedback fragment that signals dermal fibroblasts to up-regulate extracellular matrix (ECM) component synthesis. In cultured human fibroblast models, exposure to Pal-KTTKS at concentrations of 1-10 µM has been associated with increased synthesis of collagen type I, collagen type III, and collagen type IV, as well as fibronectin and glycosaminoglycans (GAGs). The mechanism is thought to involve fragment-mediated activation of TGF-β-like signaling cascades, though the exact receptor target remains under investigation.^[1]

2. Fibroblast Stimulation and ECM Remodeling. Research suggests that Pal-KTTKS treatment enhances fibroblast proliferation and migration in monolayer cultures. Downstream, this manifests as elevated mRNA expression of COL1A1, COL3A1, and FN1 genes, along with increased deposition of mature collagen fibrils in three-dimensional dermal equivalents. These effects mirror the natural wound-healing response, in which procollagen cleavage fragments act as autocrine signals to amplify ECM production.

3. Lipid-Conjugate Delivery Enhancement. The palmitoyl chain provides a delivery advantage over unconjugated KTTKS. Free KTTKS is hydrophilic (logP < 0) and shows poor penetration into the viable epidermis. Palmitoylation raises the calculated logP to approximately +3-4, which falls within the optimal Lipinski-range window for transdermal partitioning. In Franz cell diffusion studies using human skin explants, Pal-KTTKS has been shown to reach the upper dermis at concentrations sufficient to elicit fibroblast responses.^[2]

4. Comparison with Related Matrikines. Pal-KTTKS belongs to a broader class of bioactive peptides known as matrikines — ECM-derived fragments that regulate dermal cell behavior. Unlike copper-tripeptide GHK-Cu (which acts through copper-mediated metalloprotein regulation and antioxidant enzyme induction) or acetyl hexapeptide-8 (Argireline, which inhibits SNARE complex assembly in neuromuscular endings), Matrixyl works strictly within the collagen biosynthesis feedback loop. This mechanistic distinction makes Matrixyl a frequent comparator in dermal research designs evaluating ECM-targeted versus neuromodulatory cosmetic peptides.

5. Anti-Glycation and Photoaging Pathways. Emerging in vitro data also suggest that Pal-KTTKS may attenuate advanced glycation end-product (AGE) accumulation in fibroblast cultures exposed to high-glucose or UV-stress conditions, potentially by preserving the structural integrity of newly synthesized collagen. While these findings are preliminary, they expand the mechanistic profile of Matrixyl beyond simple collagen stimulation into the broader domain of photoaging research.

Matrixyl is sold as a research-grade topical solution containing palmitoyl pentapeptide-4 as the primary bioactive, formulated in a hydrophilic carrier system. Because cosmetic peptide preparations are inherently multi-ingredient, a single molecular formula does not describe the finished product. The table below details the principal active component and typical formulation matrix used in dermal research.

Active Concentration: Research-grade Matrixyl topical preparations typically contain Pal-KTTKS at 0.0003% to 0.05% (3-500 ppm), consistent with concentrations shown to elicit fibroblast responses in published in vitro and clinical work.

Physical Form: Clear to slightly opalescent aqueous-glycol solution. The palmitoyl moiety can produce mild surfactant-like properties at higher concentrations.

Purity (peptide active): The Pal-KTTKS raw material used in AminoCore Research preparations is supplied at ≥98% HPLC purity prior to formulation.

Solubility Notes: Pal-KTTKS is amphiphilic — soluble in glycol/water mixtures and ethanol but poorly soluble in pure water due to the C16 lipid tail. This solubility profile drives the use of glycol co-solvents in research preparations.

Research Use Only: This product is intended exclusively for in vitro dermal research, ex vivo skin model studies, and laboratory comparison work against related matrikines (GHK-Cu, acetyl tetrapeptide-2, palmitoyl tripeptide-1).

Matrixyl (palmitoyl pentapeptide-4) is supplied by AminoCore Research as a pre-formulated topical solution intended exclusively for in vitro dermal research, fibroblast culture studies, and topical application research models. Because the active is already solubilized in a compatible vehicle, no reconstitution from lyophilized powder is required. The following handling steps are recommended to preserve potency throughout the research period.

Preparation & Application Protocol

1. Equilibrate to room temperature. Remove the bottle from refrigerated storage and allow it to reach 20-25°C before opening. Cold solutions can cause condensation that introduces moisture and microbial contamination risk.
2. Invert gently 3-5 times. Do not shake vigorously. The palmitoyl chain on Pal-KTTKS is surface-active, and aggressive agitation can generate foam that traps peptide at the air-liquid interface and reduces effective concentration.
3. Dispense with clean implements. Use a sterile pipette, dropper, or applicator for each draw. Never apply directly from bottle to skin model or culture surface to avoid back-contamination.
4. For dermal research models (ex vivo skin, reconstructed epidermis, fibroblast monolayers), apply a thin uniform film at the manufacturer-validated concentration, typically corresponding to 3-10 ppm Pal-KTTKS at the application site.
5. Recap immediately after each use. Prolonged air exposure can oxidize the methionine-free peptide backbone is stable, but the vehicle components and any co-formulated antioxidants may degrade.
6. Avoid metal contact. Trace iron or copper ions can catalyze peptide and lipid oxidation. Use plastic or glass implements only.

Compound-Specific Handling Notes

• Lipophilic conjugate: The palmitoyl group renders Pal-KTTKS amphipathic. It will preferentially partition into lipid-rich phases — relevant when designing emulsion-based research vehicles.
• pH sensitivity: Optimal stability is in the pH 5-6 range. Avoid mixing with strongly alkaline or acidic test articles in co-application studies.
• Photostability: Pal-KTTKS itself is photostable, but the topical solution should still be kept away from direct UV/sunlight to preserve any co-formulated stabilizers.
• Incompatibility: Avoid co-application with strong oxidizers or high concentrations of vitamin C (L-ascorbic acid) in the same vehicle, which can disrupt peptide integrity over time.

This product is supplied for laboratory research use only and is not intended for human or veterinary use.

Proper storage is essential to maintain the integrity of palmitoyl pentapeptide-4 (Pal-KTTKS) and the topical solution vehicle. Research-grade peptide formulations are sensitive to temperature, light, oxygen, and microbial contamination, and inappropriate storage can reduce active concentration well before the labeled expiration date.

Recommended Storage Conditions

• Long-term storage (unopened): Refrigerate at 2-8°C in the original sealed container. Under these conditions, the topical solution retains research-grade potency for the duration of the labeled shelf life (typically 18-24 months from manufacture).
• Short-term / in-use storage (opened): Keep refrigerated at 2-8°C between uses. Once opened, use within 60-90 days to ensure consistent concentration and microbial integrity.
• Transit / shipping: Brief exposure to ambient temperature (up to 25°C) for several days during shipping does not appreciably degrade Pal-KTTKS, which is one of the more thermally stable cosmetic peptides.
• Freezing: Not recommended. Freeze-thaw cycles can disrupt the emulsion or solution structure of the vehicle even though the peptide itself tolerates freezing.

Compound-Specific Stability Notes

• No disulfide bonds: The KTTKS sequence (Lys-Thr-Thr-Lys-Ser) contains no cysteine residues, so disulfide rearrangement — a common degradation pathway for many research peptides — is not a concern.
• No methionine or tryptophan: The peptide lacks oxidation-sensitive Met and Trp residues, contributing to its favorable shelf stability profile compared to peptides like Thymosin Alpha-1 or Semax.
• Lipid hydrolysis: The primary degradation pathway is slow hydrolysis of the amide bond linking palmitic acid to the lysine N-terminus, which would yield free KTTKS (with substantially lower transdermal bioavailability) and palmitic acid. This is minimized by refrigerated storage and neutral-to-slightly-acidic vehicle pH.
• Microbial considerations: Topical solutions typically contain a preservative system; nonetheless, avoid introducing contamination via shared applicators.
• Light: Store in the original opaque or amber container away from direct light.

Discard any solution showing visible cloudiness, phase separation, color change, or off-odor, regardless of the labeled expiration date.